Semaglutide | List of Frontiers open access articles

Original Research

Published on 20 Mar 2025

Semaglutide attenuates myocardial ischemia-reperfusion injury by inhibiting ferroptosis of cardiomyocytes via activation of PKC-S100A9 axis

in Cardiovascular and Smooth Muscle Pharmacology

Yan Liu
Zixuan Li
Xinhe Xu
Yan Zou
Miaomiao Zhang
Yingyu Chen
Wenwu Zhu
Bing Han

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1529652

5,388 views
11 citations

Original Research

Published on 10 Jun 2021

Exploring the Appropriate Price of Semaglutide for Type 2 Diabetes Patients Based on Cost-Utility Analysis in China

in Drugs Outcomes Research and Policies

Shanshan Hu
Xiaorong Su
Xun Deng
Yong Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2021.701446

10,101 views
9 citations

Original Research

Published on 11 Apr 2024

The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study

in Obesity

Mojca Jensterle
Simona Ferjan
Andrej Janez

Frontiers in Endocrinology

doi 10.3389/fendo.2024.1366940

28,941 views
33 citations

Review

Published on 25 Jun 2021

Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation

in Clinical Diabetes

Juris J. Meier

Frontiers in Endocrinology

doi 10.3389/fendo.2021.645617

141,393 views
113 citations

Original Research

Published on 02 Jun 2025

Effects of semaglutide on metabolism and gut microbiota in high-fat diet-induced obese mice

in Gastrointestinal and Hepatic Pharmacology

Luyan Sun
Bingqing Shang
Suyuan Lv
Guolong Liu
Qiu Wu
Yue Geng

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1562896

9,422 views
20 citations

Original Research

Published on 10 Mar 2025

Semaglutide promotes the proliferation and osteogenic differentiation of bone-derived mesenchymal stem cells through activation of the Wnt/LRP5/β-catenin signaling pathway

in Experimental Pharmacology and Drug Discovery

Yawei Tian
Huiming Liu
Xiaoxue Bao
Yukun Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1539411

7,630 views
14 citations

Original Research

Published on 24 Dec 2021

Comparative Cardio-Renal Outcomes of Type 2 Diabetes Patients Administered Glucagon-Like Peptide-1 Receptor Agonists: A Network Meta-Analysis

in Cardiovascular and Smooth Muscle Pharmacology

Chuanjun Zhuo
Chongguang Lin
Chunhua Zhou
Xiangyang Gao
Hailin Shao
Tao Fang
Hongjun Tian
Li Ding
Ming Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2021.759262

10,046 views
4 citations

Review

Published on 07 Jul 2021

Safety of Semaglutide

in Clinical Diabetes

Mark M. Smits
Daniël H. Van Raalte

Frontiers in Endocrinology

doi 10.3389/fendo.2021.645563

424,301 views
305 citations

Case Report

Published on 29 Aug 2023

Case Report: Semaglutide-associated depression: a report of two cases

in Mood Disorders

Jia-Rui Li
Jinya Cao
Jing Wei
Wenqi Geng

Frontiers in Psychiatry

doi 10.3389/fpsyt.2023.1238353

40,580 views
48 citations

Original Research

Published on 09 Dec 2022

Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model

in Obesity

Shu Niu
Shuchun Chen
Xing Chen
Qingjuan Ren
Lin Yue
Xiaoyu Pan
Huiying Zhao
Zelin Li
Xiaoyi Chen

Frontiers in Endocrinology

doi 10.3389/fendo.2022.1046130

37,670 views
62 citations

Systematic Review

Published on 05 Jul 2024

Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis

in Clinical and Translational Cardiovascular Medicine

Walter Masson
Martín Lobo
Juan Patricio Nogueira
Alfredo Matias Rodriguez-Granillo
Leandro Ezequiel Barbagelata
Daniel Siniawski

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2024.1379189

16,631 views
43 citations

Systematic Review

Published on 06 Oct 2021

Efficacy and Safety of Subcutaneous and Oral Semaglutide Administration in Patients With Type 2 Diabetes: A Meta-Analysis

in Drugs Outcomes Research and Policies

Ping Zhong
Hai Zeng
Miaochun Huang
Guoxin He
Zhixia Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2021.695182

14,315 views
20 citations

Original Research

Published on 03 Jun 2024

Adverse events in different administration routes of semaglutide: a pharmacovigilance study based on the FDA adverse event reporting system

in Drugs Outcomes Research and Policies

Kaibin Niu
Maoxia Fan
Wulin Gao
Chen Chen
Guohua Dai

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1414268

12,698 views
18 citations

Original Research

Published on 07 Oct 2024

SGLT2i and GLP1-RA exert additive cardiorenal protection with a RAS blocker in uninephrectomized db/db mice

in Renal Pharmacology

Nerea Martos-Guillami
Ander Vergara
Carmen Llorens-Cebrià
Aku Enam Motto
Irene Martínez-Díaz
Francisco Gonçalves
Maria Magdalena Garcias-Ramis
Estibaliz Allo-Urzainqui
Alonso Narváez
Sheila Bermejo

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1415879

6,321 views
8 citations

Case Report

Published on 21 Jan 2025

Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review

in Obesity

Andrijana Koceva
Katarina Mlekuš Kozamernik
Andrej Janež
Rok Herman
Simona Ferjan
Mojca Jensterle

Frontiers in Endocrinology

doi 10.3389/fendo.2024.1528457

11,882 views
3 citations

Review

Published on 28 Aug 2023

Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review

in Obesity

Zeyu Xie
Jia Hu
Hangye Gu
Mengting Li
Jisheng Chen

Frontiers in Endocrinology

doi 10.3389/fendo.2023.1244432

25,273 views
43 citations

Articles

Semaglutide attenuates myocardial ischemia-reperfusion injury by inhibiting ferroptosis of cardiomyocytes via activation of PKC-S100A9 axis

Exploring the Appropriate Price of Semaglutide for Type 2 Diabetes Patients Based on Cost-Utility Analysis in China

The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study

Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation

Effects of semaglutide on metabolism and gut microbiota in high-fat diet-induced obese mice

Semaglutide promotes the proliferation and osteogenic differentiation of bone-derived mesenchymal stem cells through activation of the Wnt/LRP5/β-catenin signaling pathway

Comparative Cardio-Renal Outcomes of Type 2 Diabetes Patients Administered Glucagon-Like Peptide-1 Receptor Agonists: A Network Meta-Analysis

Safety of Semaglutide

Case Report: Semaglutide-associated depression: a report of two cases

Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model

Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis

Efficacy and Safety of Subcutaneous and Oral Semaglutide Administration in Patients With Type 2 Diabetes: A Meta-Analysis

Adverse events in different administration routes of semaglutide: a pharmacovigilance study based on the FDA adverse event reporting system

SGLT2i and GLP1-RA exert additive cardiorenal protection with a RAS blocker in uninephrectomized db/db mice

Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review

Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review